EVOMMUNE INC (EVMN) competitors & alternatives
Health Care · NYSE
EVOMMUNE INC (EVMN)'s top competitors and alternatives — its most similar public companies — include BIOHAVEN LTD (BHVN), IMMUNOVANT INC (IMVT), KYVERNA THERAPEUTICS INC (KYTX), ELEDON PHARMACEUTICALS INC (ELDN), AVALYN PHARMA INC (AVLN), CULLINAN THERAPEUTICS INC (CGEM), NURIX THERAPEUTICS INC (NRIX), ANAPTYSBIO INC (ANAB), TONIX PHARMACEUTICALS HOLDING CORP (TNXP), ARCUS BIOSCIENCES INC (RCUS), Aardvark Therapeutics, Inc. (AARD) and TENAX THERAPEUTICS INC (TENX). These are EVOMMUNE INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top EVMN competitors & alternatives
-
BIOHAVEN LTDBHVNHealth Care
Biohaven is a clinical-stage biopharmaceutical company developing innovative therapies for immunology, neurological disorders, and metabolic diseases using…
$14.75 (as of 2026-07-22) · market cap $2.3B
-
IMMUNOVANT INCIMVTHealth Care
Immunovant is a clinical-stage immunology company developing IMVT-1402, a potentially best-in-class FcRn inhibitor to treat autoimmune diseases driven by…
$39.05 (as of 2026-07-22) · market cap $8.0B
-
KYVERNA THERAPEUTICS INCKYTXHealth Care
Kyverna is a clinical-stage immunology biotech developing novel investigational therapeutics with no approved products and complete dependence on successful…
$7.40 (as of 2026-07-22) · market cap $452M
-
ELEDON PHARMACEUTICALS INCELDNHealth Care
Eledon Pharmaceuticals is a clinical-stage biotech developing immune-modulating therapies for autoimmune diseases and organ transplantation.
$3.72 (as of 2026-07-22) · market cap $287M
-
AVALYN PHARMA INCAVLNHealth Care
Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled drug formulations for the treatment of rare respiratory diseases.
$28.72 (as of 2026-07-22) · market cap $1.3B
-
CULLINAN THERAPEUTICS INCCGEMHealth Care
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing targeted, innovative therapies for cancer and autoimmune diseases.
$17.65 (as of 2026-07-22) · market cap $1.1B
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
-
ANAPTYSBIO INCANABHealth Care
AnaptysBio is an immunotherapy company generating revenue from blockbuster royalties (Jemperli with GSK, imsidolimab with Vanda) while pursuing its own…
$52.61 (as of 2026-07-22) · market cap $1.6B
-
TONIX PHARMACEUTICALS HOLDING CORPTNXPHealth Care
A fully-integrated biopharmaceutical company commercializing TONMYA (cyclobenzaprine sublingual tablets) for fibromyalgia while advancing a pipeline of CNS,…
$10.59 (as of 2026-07-22) · market cap $184M
-
ARCUS BIOSCIENCES INCRCUSHealth Care
A clinical-stage biotech developing first-in-class and best-in-class small molecules and antibodies for cancer immunotherapy, with lead HIF-2α inhibitor in…
$29.97 (as of 2026-07-22) · market cap $3.7B
-
Aardvark Therapeutics, Inc.AARDHealth Care
Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing its lead small molecule candidate, ARD-101, for metabolic and rare disease…
$6.48 (as of 2026-07-22) · market cap $128M
-
TENAX THERAPEUTICS INCTENXHealth Care
A Phase 3 development-stage pharmaceutical company developing novel cardiopulmonary therapies, primarily levosimendan for pulmonary hypertension and imatinib…
$14.79 (as of 2026-07-22) · market cap $418M
Not quite? Describe exactly what you want →
Peers are EVOMMUNE INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: EVOMMUNE INC (EVMN).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.